Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 143 | 2023 | 5221 | 12.850 |
Why?
|
Receptor Protein-Tyrosine Kinases | 68 | 2023 | 1660 | 11.000 |
Why?
|
Lung Neoplasms | 177 | 2023 | 13102 | 10.880 |
Why?
|
Protein Kinase Inhibitors | 99 | 2023 | 5535 | 8.210 |
Why?
|
Pyrazoles | 70 | 2023 | 1972 | 7.590 |
Why?
|
Lactams, Macrocyclic | 25 | 2023 | 320 | 6.770 |
Why?
|
Pyridines | 51 | 2022 | 2825 | 5.720 |
Why?
|
Protein-Tyrosine Kinases | 33 | 2023 | 2455 | 5.710 |
Why?
|
Carbazoles | 18 | 2022 | 226 | 5.050 |
Why?
|
Drug Resistance, Neoplasm | 49 | 2023 | 5172 | 4.360 |
Why?
|
Proto-Oncogene Proteins | 31 | 2021 | 4554 | 4.310 |
Why?
|
Gene Rearrangement | 28 | 2019 | 1179 | 4.150 |
Why?
|
Sulfones | 17 | 2021 | 437 | 3.730 |
Why?
|
Piperidines | 19 | 2021 | 1602 | 3.230 |
Why?
|
Antineoplastic Agents | 49 | 2023 | 13695 | 2.770 |
Why?
|
Lactams | 21 | 2023 | 156 | 2.500 |
Why?
|
Oncogene Proteins, Fusion | 19 | 2021 | 1581 | 2.400 |
Why?
|
Pyrimidines | 24 | 2021 | 2942 | 2.300 |
Why?
|
Aminopyridines | 22 | 2023 | 542 | 2.060 |
Why?
|
Mutation | 58 | 2023 | 29786 | 1.410 |
Why?
|
Brain Neoplasms | 17 | 2022 | 8863 | 1.360 |
Why?
|
Proto-Oncogene Proteins c-ret | 5 | 2018 | 220 | 1.200 |
Why?
|
Indazoles | 5 | 2019 | 289 | 0.960 |
Why?
|
Translocation, Genetic | 6 | 2016 | 1420 | 0.950 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 17 | 2021 | 11524 | 0.890 |
Why?
|
Taxoids | 6 | 2017 | 666 | 0.880 |
Why?
|
Adenocarcinoma | 12 | 2018 | 6364 | 0.850 |
Why?
|
ras Proteins | 7 | 2015 | 1060 | 0.850 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 1692 | 0.800 |
Why?
|
Humans | 199 | 2023 | 744343 | 0.780 |
Why?
|
Benzamides | 6 | 2021 | 1379 | 0.760 |
Why?
|
Genes, erbB-1 | 2 | 2017 | 161 | 0.640 |
Why?
|
Platinum | 1 | 2019 | 233 | 0.630 |
Why?
|
Receptor, trkA | 4 | 2020 | 164 | 0.620 |
Why?
|
Molecular Targeted Therapy | 16 | 2023 | 2727 | 0.610 |
Why?
|
Genetic Heterogeneity | 3 | 2017 | 733 | 0.610 |
Why?
|
In Situ Hybridization, Fluorescence | 11 | 2020 | 2649 | 0.600 |
Why?
|
Drug Resistance | 2 | 2013 | 1609 | 0.590 |
Why?
|
Prognosis | 27 | 2022 | 29063 | 0.590 |
Why?
|
Middle Aged | 84 | 2021 | 213383 | 0.570 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2019 | 2043 | 0.570 |
Why?
|
Aged | 72 | 2021 | 163280 | 0.550 |
Why?
|
Adult | 76 | 2021 | 214055 | 0.520 |
Why?
|
Organophosphorus Compounds | 4 | 2018 | 215 | 0.520 |
Why?
|
Proto-Oncogene Proteins c-met | 7 | 2021 | 578 | 0.510 |
Why?
|
Anilides | 3 | 2022 | 408 | 0.510 |
Why?
|
Neoplasms | 12 | 2020 | 21683 | 0.500 |
Why?
|
Female | 99 | 2021 | 380194 | 0.500 |
Why?
|
Genomic Instability | 2 | 2023 | 695 | 0.490 |
Why?
|
Guanine | 2 | 2013 | 274 | 0.490 |
Why?
|
Glutamates | 2 | 2013 | 398 | 0.490 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 255 | 0.470 |
Why?
|
Male | 91 | 2021 | 350118 | 0.460 |
Why?
|
Puerperal Disorders | 1 | 2016 | 275 | 0.460 |
Why?
|
Meningeal Carcinomatosis | 1 | 2013 | 65 | 0.450 |
Why?
|
Clinical Trials, Phase I as Topic | 5 | 2019 | 323 | 0.440 |
Why?
|
Disease-Free Survival | 12 | 2017 | 6895 | 0.430 |
Why?
|
Aged, 80 and over | 40 | 2021 | 57776 | 0.430 |
Why?
|
HSP90 Heat-Shock Proteins | 4 | 2018 | 434 | 0.420 |
Why?
|
Cell Line, Tumor | 20 | 2021 | 16689 | 0.410 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2529 | 0.380 |
Why?
|
Immunotherapy | 7 | 2018 | 4445 | 0.370 |
Why?
|
Genes, ras | 4 | 2009 | 690 | 0.370 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2019 | 10943 | 0.350 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2013 | 484 | 0.340 |
Why?
|
Survival Rate | 9 | 2019 | 12788 | 0.340 |
Why?
|
Central Nervous System Neoplasms | 4 | 2017 | 895 | 0.330 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2019 | 388 | 0.330 |
Why?
|
Treatment Outcome | 27 | 2019 | 63114 | 0.330 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 1213 | 0.330 |
Why?
|
Acrylamides | 4 | 2018 | 255 | 0.320 |
Why?
|
Loss of Heterozygosity | 1 | 2010 | 684 | 0.320 |
Why?
|
Young Adult | 26 | 2021 | 56430 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 11 | 2018 | 6538 | 0.300 |
Why?
|
Tumor Burden | 5 | 2020 | 1915 | 0.290 |
Why?
|
Maximum Tolerated Dose | 4 | 2020 | 892 | 0.290 |
Why?
|
Gene Fusion | 2 | 2019 | 371 | 0.280 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2021 | 8428 | 0.280 |
Why?
|
Spinal Neoplasms | 1 | 2013 | 760 | 0.280 |
Why?
|
Retrospective Studies | 26 | 2022 | 77449 | 0.270 |
Why?
|
Drug Hypersensitivity | 1 | 2014 | 884 | 0.270 |
Why?
|
Clinical Trials as Topic | 9 | 2020 | 7913 | 0.270 |
Why?
|
Hypogonadism | 1 | 2012 | 799 | 0.270 |
Why?
|
Meningeal Neoplasms | 1 | 2015 | 1241 | 0.260 |
Why?
|
Neoplasm Staging | 12 | 2020 | 11031 | 0.260 |
Why?
|
Quinazolines | 4 | 2018 | 1356 | 0.260 |
Why?
|
Survival Analysis | 6 | 2020 | 10252 | 0.260 |
Why?
|
Biopsy | 8 | 2021 | 6756 | 0.260 |
Why?
|
Patient Selection | 4 | 2020 | 4215 | 0.250 |
Why?
|
Aspartate Aminotransferases | 2 | 2017 | 418 | 0.250 |
Why?
|
Gene Amplification | 3 | 2020 | 1063 | 0.250 |
Why?
|
Retreatment | 2 | 2017 | 610 | 0.250 |
Why?
|
DNA Mutational Analysis | 7 | 2019 | 4186 | 0.250 |
Why?
|
Follow-Up Studies | 12 | 2019 | 39050 | 0.250 |
Why?
|
Neoplasm Metastasis | 6 | 2022 | 4851 | 0.240 |
Why?
|
Immunohistochemistry | 6 | 2020 | 11366 | 0.240 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 169 | 0.240 |
Why?
|
Drug Delivery Systems | 2 | 2013 | 2219 | 0.240 |
Why?
|
Intention to Treat Analysis | 3 | 2020 | 426 | 0.240 |
Why?
|
Receptor, trkB | 3 | 2019 | 125 | 0.240 |
Why?
|
Alanine Transaminase | 2 | 2017 | 592 | 0.230 |
Why?
|
Genotype | 8 | 2017 | 12951 | 0.230 |
Why?
|
Disease Progression | 10 | 2020 | 13284 | 0.220 |
Why?
|
Tomography, X-Ray Computed | 10 | 2019 | 20129 | 0.220 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 61 | 0.200 |
Why?
|
Animals | 25 | 2020 | 168757 | 0.200 |
Why?
|
Testosterone | 1 | 2012 | 2420 | 0.200 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 252 | 0.200 |
Why?
|
Homeodomain Proteins | 1 | 2010 | 2421 | 0.190 |
Why?
|
Lung | 5 | 2019 | 9856 | 0.190 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2019 | 3557 | 0.190 |
Why?
|
Food-Drug Interactions | 1 | 2020 | 27 | 0.190 |
Why?
|
Hepatocyte Growth Factor | 1 | 2021 | 270 | 0.180 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4933 | 0.180 |
Why?
|
Oxidative Stress | 1 | 2011 | 3086 | 0.180 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 3597 | 0.180 |
Why?
|
Phospholipase D | 1 | 2019 | 70 | 0.170 |
Why?
|
Aniline Compounds | 3 | 2018 | 986 | 0.170 |
Why?
|
Radiosurgery | 3 | 2018 | 1329 | 0.170 |
Why?
|
Mice | 17 | 2020 | 81183 | 0.170 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2017 | 730 | 0.170 |
Why?
|
Resorcinols | 1 | 2018 | 38 | 0.160 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2019 | 200 | 0.160 |
Why?
|
Pyridazines | 1 | 2020 | 202 | 0.160 |
Why?
|
Ethylnitrosourea | 1 | 2018 | 51 | 0.160 |
Why?
|
Carcinoma, Large Cell | 1 | 2018 | 113 | 0.160 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1791 | 0.160 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2017 | 337 | 0.160 |
Why?
|
Combined Modality Therapy | 4 | 2018 | 8642 | 0.150 |
Why?
|
Imidazoles | 2 | 2021 | 1206 | 0.150 |
Why?
|
Disease Models, Animal | 6 | 2019 | 18029 | 0.150 |
Why?
|
Drug Discovery | 2 | 2016 | 1058 | 0.150 |
Why?
|
Isoxazoles | 1 | 2018 | 216 | 0.150 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2018 | 234 | 0.150 |
Why?
|
gamma-Glutamyltransferase | 1 | 2017 | 134 | 0.150 |
Why?
|
Platinum Compounds | 1 | 2017 | 96 | 0.140 |
Why?
|
Oncogene Fusion | 1 | 2017 | 99 | 0.140 |
Why?
|
Transcription Factors | 2 | 2020 | 12208 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9239 | 0.140 |
Why?
|
Bone Morphogenetic Protein 3 | 1 | 2016 | 17 | 0.140 |
Why?
|
Genes, erbB-2 | 1 | 2017 | 162 | 0.140 |
Why?
|
Genomics | 5 | 2023 | 5720 | 0.140 |
Why?
|
Eligibility Determination | 1 | 2020 | 403 | 0.140 |
Why?
|
Gene Order | 1 | 2016 | 176 | 0.140 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2018 | 890 | 0.140 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 4751 | 0.140 |
Why?
|
Mutagenesis, Insertional | 1 | 2018 | 655 | 0.130 |
Why?
|
Protein Conformation | 2 | 2014 | 4011 | 0.130 |
Why?
|
DNA, Neoplasm | 2 | 2018 | 1758 | 0.130 |
Why?
|
Hyperlipidemias | 1 | 2020 | 789 | 0.130 |
Why?
|
Mice, Nude | 4 | 2020 | 3689 | 0.130 |
Why?
|
Endpoint Determination | 2 | 2016 | 601 | 0.130 |
Why?
|
Peripartum Period | 1 | 2016 | 133 | 0.130 |
Why?
|
Thoracic Neoplasms | 1 | 2017 | 268 | 0.130 |
Why?
|
DNA Helicases | 1 | 2020 | 859 | 0.130 |
Why?
|
Organoplatinum Compounds | 1 | 2016 | 408 | 0.120 |
Why?
|
Family Characteristics | 1 | 2019 | 1000 | 0.120 |
Why?
|
Scleroderma, Localized | 1 | 2015 | 79 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 358 | 0.120 |
Why?
|
Cohort Studies | 6 | 2019 | 40561 | 0.120 |
Why?
|
Benzoquinones | 1 | 2014 | 201 | 0.120 |
Why?
|
Exons | 2 | 2018 | 2437 | 0.120 |
Why?
|
Membrane Glycoproteins | 3 | 2019 | 3768 | 0.120 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 809 | 0.120 |
Why?
|
Inhibitory Concentration 50 | 1 | 2014 | 459 | 0.120 |
Why?
|
Creatine Kinase | 1 | 2015 | 694 | 0.120 |
Why?
|
Liver Failure | 1 | 2015 | 241 | 0.120 |
Why?
|
Arthritis, Experimental | 1 | 2016 | 291 | 0.120 |
Why?
|
Kidney Diseases, Cystic | 1 | 2015 | 186 | 0.110 |
Why?
|
Time Factors | 5 | 2019 | 40075 | 0.110 |
Why?
|
Codon | 1 | 2015 | 611 | 0.110 |
Why?
|
Quality of Life | 5 | 2020 | 12804 | 0.110 |
Why?
|
Thymidylate Synthase | 1 | 2012 | 75 | 0.110 |
Why?
|
Structure-Activity Relationship | 2 | 2021 | 3129 | 0.110 |
Why?
|
Administration, Oral | 3 | 2017 | 3913 | 0.110 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2019 | 629 | 0.110 |
Why?
|
Gene Deletion | 1 | 2020 | 2751 | 0.110 |
Why?
|
Piperazines | 3 | 2019 | 2488 | 0.100 |
Why?
|
Cell Proliferation | 4 | 2017 | 10481 | 0.100 |
Why?
|
Language | 1 | 2021 | 1471 | 0.100 |
Why?
|
Internationality | 1 | 2017 | 1003 | 0.100 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1677 | 0.100 |
Why?
|
Alleles | 2 | 2021 | 6933 | 0.100 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.100 |
Why?
|
Edema | 1 | 2015 | 789 | 0.100 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 713 | 0.100 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 2635 | 0.100 |
Why?
|
Oncogenes | 2 | 2016 | 1265 | 0.100 |
Why?
|
Molecular Structure | 1 | 2015 | 1899 | 0.100 |
Why?
|
Benzimidazoles | 2 | 2015 | 850 | 0.100 |
Why?
|
Enzyme Inhibitors | 3 | 2017 | 3798 | 0.100 |
Why?
|
Immunoblotting | 2 | 2012 | 1682 | 0.100 |
Why?
|
Constipation | 1 | 2015 | 546 | 0.100 |
Why?
|
Enzyme Activation | 2 | 2014 | 3701 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1897 | 0.090 |
Why?
|
Protein Stability | 1 | 2012 | 557 | 0.090 |
Why?
|
Osteoblasts | 1 | 2016 | 1166 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2021 | 3508 | 0.090 |
Why?
|
Cell Survival | 2 | 2019 | 5882 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2011 | 602 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2007 | 7880 | 0.090 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1017 | 0.090 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 547 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6489 | 0.090 |
Why?
|
Diagnostic Imaging | 2 | 2019 | 3507 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2016 | 1023 | 0.080 |
Why?
|
Prospective Studies | 6 | 2019 | 53288 | 0.080 |
Why?
|
Recombination, Genetic | 1 | 2014 | 1586 | 0.080 |
Why?
|
Models, Molecular | 2 | 2021 | 5456 | 0.080 |
Why?
|
Hydroxychloroquine | 1 | 2012 | 412 | 0.080 |
Why?
|
Receptor, trkC | 2 | 2019 | 68 | 0.080 |
Why?
|
Cell Lineage | 1 | 2017 | 2504 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2459 | 0.080 |
Why?
|
Melanoma | 2 | 2017 | 5510 | 0.080 |
Why?
|
Fatigue | 1 | 2015 | 1531 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1850 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2018 | 4034 | 0.080 |
Why?
|
Australia | 1 | 2011 | 1170 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 2503 | 0.080 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 2 | 2021 | 318 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1671 | 0.080 |
Why?
|
Microfluidics | 1 | 2013 | 662 | 0.080 |
Why?
|
Recurrence | 1 | 2019 | 8340 | 0.080 |
Why?
|
Fibroblasts | 2 | 2011 | 4161 | 0.070 |
Why?
|
Embryo Loss | 1 | 2007 | 59 | 0.070 |
Why?
|
Triazoles | 1 | 2013 | 911 | 0.070 |
Why?
|
Environment | 1 | 2013 | 1124 | 0.070 |
Why?
|
Vision Disorders | 1 | 2014 | 1058 | 0.070 |
Why?
|
Cell Separation | 1 | 2013 | 1751 | 0.070 |
Why?
|
Genetic Markers | 1 | 2013 | 2634 | 0.070 |
Why?
|
Binding Sites | 1 | 2015 | 6114 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2018 | 3505 | 0.070 |
Why?
|
DNA Primers | 1 | 2011 | 2892 | 0.070 |
Why?
|
Adolescent | 6 | 2019 | 85781 | 0.070 |
Why?
|
Thrombosis | 1 | 2020 | 2968 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 934 | 0.070 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 1375 | 0.070 |
Why?
|
Deglutition Disorders | 1 | 2011 | 605 | 0.070 |
Why?
|
Mice, SCID | 3 | 2018 | 2716 | 0.070 |
Why?
|
Cell Death | 1 | 2011 | 1706 | 0.070 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 6314 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5853 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1564 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 1988 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2038 | 0.060 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2007 | 3617 | 0.060 |
Why?
|
Signal Transduction | 5 | 2021 | 23403 | 0.060 |
Why?
|
Cranial Irradiation | 2 | 2018 | 401 | 0.060 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2021 | 1475 | 0.060 |
Why?
|
Self Report | 1 | 2014 | 3558 | 0.060 |
Why?
|
Reactive Oxygen Species | 1 | 2011 | 2077 | 0.060 |
Why?
|
Glucuronosyltransferase | 1 | 2023 | 128 | 0.060 |
Why?
|
Uridine | 1 | 2023 | 146 | 0.060 |
Why?
|
Risk Assessment | 2 | 2017 | 23338 | 0.060 |
Why?
|
Transfection | 1 | 2011 | 5892 | 0.050 |
Why?
|
Germ-Line Mutation | 2 | 2009 | 1788 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2023 | 2948 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8949 | 0.050 |
Why?
|
Risk Factors | 4 | 2020 | 72290 | 0.050 |
Why?
|
Smoking | 1 | 2019 | 8987 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15540 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 9959 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2016 | 13033 | 0.050 |
Why?
|
Pregnancy | 2 | 2016 | 29144 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2011 | 5974 | 0.050 |
Why?
|
Apoptosis | 2 | 2019 | 9727 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4253 | 0.040 |
Why?
|
Phosphorylation | 1 | 2011 | 8436 | 0.040 |
Why?
|
Receptors, Growth Factor | 2 | 2010 | 334 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2007 | 1526 | 0.040 |
Why?
|
Genetic Engineering | 1 | 2005 | 951 | 0.040 |
Why?
|
Congenital Abnormalities | 1 | 2004 | 707 | 0.040 |
Why?
|
Drug Interactions | 1 | 2023 | 1460 | 0.040 |
Why?
|
Triazines | 1 | 2021 | 315 | 0.040 |
Why?
|
Genetic Testing | 1 | 2011 | 3444 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 594 | 0.040 |
Why?
|
Keratin-8 | 1 | 2017 | 11 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2011 | 12959 | 0.040 |
Why?
|
Keratin-18 | 1 | 2017 | 39 | 0.040 |
Why?
|
Immunoprecipitation | 1 | 2020 | 905 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5686 | 0.040 |
Why?
|
INDEL Mutation | 1 | 2018 | 279 | 0.040 |
Why?
|
Neurofibromin 1 | 1 | 2018 | 196 | 0.040 |
Why?
|
Mice, Transgenic | 2 | 2007 | 9734 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6773 | 0.040 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2020 | 377 | 0.040 |
Why?
|
Phthalazines | 1 | 2019 | 363 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12354 | 0.040 |
Why?
|
RNA | 1 | 2007 | 2749 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2915 | 0.040 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2007 | 2916 | 0.030 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2016 | 91 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15076 | 0.030 |
Why?
|
Base Sequence | 1 | 2007 | 12797 | 0.030 |
Why?
|
Sex Factors | 1 | 2009 | 10397 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 625 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2011 | 19229 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2020 | 736 | 0.030 |
Why?
|
Cell Cycle Proteins | 2 | 2020 | 3462 | 0.030 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 146 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 841 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 105 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9583 | 0.030 |
Why?
|
Quinazolinones | 1 | 2016 | 221 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2004 | 2942 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 2007 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2015 | 677 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2505 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1878 | 0.030 |
Why?
|
Dermatitis | 1 | 2015 | 197 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2020 | 1613 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2203 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2020 | 21827 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1364 | 0.030 |
Why?
|
Age Factors | 1 | 2009 | 18370 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4217 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2012 | 0.030 |
Why?
|
Albumins | 1 | 2015 | 569 | 0.030 |
Why?
|
Cell Shape | 1 | 2013 | 375 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2007 | 14557 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 944 | 0.030 |
Why?
|
Carboplatin | 1 | 2015 | 801 | 0.030 |
Why?
|
Skull | 1 | 2016 | 813 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2018 | 1094 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1534 | 0.020 |
Why?
|
Cell Size | 1 | 2013 | 643 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1655 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 20947 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1038 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 769 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 1941 | 0.020 |
Why?
|
Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
Drug Approval | 1 | 2016 | 742 | 0.020 |
Why?
|
Mass Screening | 1 | 2005 | 5255 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3586 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2015 | 1265 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 295 | 0.020 |
Why?
|
United States | 2 | 2018 | 69872 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2327 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5179 | 0.020 |
Why?
|
Paclitaxel | 1 | 2015 | 1708 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3521 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2924 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 783 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1086 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 1072 | 0.020 |
Why?
|
Anticoagulants | 1 | 2020 | 4599 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7799 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2016 | 4420 | 0.020 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2004 | 90 | 0.020 |
Why?
|
Genetics, Population | 1 | 2009 | 934 | 0.020 |
Why?
|
Pilot Projects | 1 | 2016 | 8324 | 0.010 |
Why?
|
Crosses, Genetic | 1 | 2004 | 791 | 0.010 |
Why?
|
Genes, p53 | 1 | 2005 | 755 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6171 | 0.010 |
Why?
|
Integrases | 1 | 2004 | 533 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2005 | 1866 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2004 | 705 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 5987 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1770 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2018 | 35421 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4149 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2004 | 1701 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2005 | 3479 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2005 | 1376 | 0.010 |
Why?
|
Viral Proteins | 1 | 2004 | 1900 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4568 | 0.010 |
Why?
|
Cell Cycle | 1 | 2004 | 2967 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2010 | 6234 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16365 | 0.010 |
Why?
|
Brain | 1 | 2018 | 26385 | 0.010 |
Why?
|
Stem Cells | 1 | 2004 | 3567 | 0.010 |
Why?
|
Child | 1 | 2018 | 77709 | 0.010 |
Why?
|